Skip to content
OpenCapital
Get started

MaxCyte MXCT EBIT

EBIT at other companies

Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$71.37M+11.9%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.8M-131%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$13.85M-18.8%
PDE
Pro-Dex, Inc.PDEX
$3.09M-15.0%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S4×-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Calculated from MaxCyte’s reported figures.

−$6.2Moperating income−$4.8Mincome before tax=-$6.19M

Plus components not separately reported this period.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's EBIT?
MaxCyte (MXCT) reported EBIT of -$6.19M in Q1 2026.
How has MaxCyte's EBIT changed year-over-year?
MaxCyte's EBIT increased by 49.7% year-over-year, from -$12.3M to -$6.19M.
What is the long-term trend for MaxCyte's EBIT?
Over 4 years (2021 to 2025), MaxCyte's EBIT has grown at a 30.0% compound annual growth rate (CAGR), from -$18.19M to -$51.9M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.